세계의 자궁경부암 진단 시장 규모, 점유율, 산업 동향 분석 보고서 : 유형별(자궁경부 세포진 검사,질 확대경 검사, HPV 검사, 생검 및 ECC), 연령대별(20-40세, 40세 이상), 지역별 전망 및 예측(2023-2029년)

The Global Cervical Cancer Diagnostic Market size is expected to reach $10.2 billion by 2029, rising at a market growth of 4.4% CAGR during the forecast period.

Asia Pacific is the promising region for cervical cancer diagnostic because rise in the prevalence of obesity among women, an increase in instances of hazardous sexual behavior, particularly among adolescents, and an increase in the number of diverse strategies and trends adopted by market participants. Hence, APAC generated $1,929.4 million revenue in the market in 2022. Numerous public-private partnerships, rising R&D efforts, and strategic initiatives by market participants are creating opportunities for the market in the region.

The major strategies followed by the market participants are Partnerships as the key developmental strategy to keep pace with the changing demands of end users. For instance, In July 2021, QIAGEN partnered with Sysmex Corporation for developing cancer companion diagnostics by utilizing Qiagen's expertise and Sysmex's Plasma-Safe-SeqS technology. The partnership provides the company with NGS capabilities and would allow the company to serve its partners in a better way. Additionally, In August 2022, Becton, Dickinson, and Company announced a partnership with LabCorp for developing and selling flow cytometry-based companion diagnostics (CDx). The partnership allows BD to serve its customers in a better way by providing solutions for cancer diagnostics.

Based on the Analysis presented in the KBV Cardinal matrix; F. Hoffmann-La Roche Ltd. is the forerunner in the Market. In May 2023, Roche Diagnostics signed an agreement with Cancer Awareness Prevention and Early Detection Trust (CAPED) for improving the situation of cervical cancer in India. The partnership is part of Roche's efforts to enhance cancer care around the world. Companies such as Abbott Laboratories, Thermo Fisher Scientific, Inc., Becton, Dickinson and Company are some of the key innovators in Market.

Market Growth Factors

Increasing initiatives for the treatment and diagnosis of cancer

Healthcare expenditures have increased globally as disposable income has risen in various countries. In addition, government bodies and healthcare organizations are accelerating healthcare expenditures to meet population requirements. As cervical cancer has become increasingly prevalent in recent years, the increase in healthcare expenditures enables healthcare institutions to enhance their diagnostic and therapeutic facilities for the disease. In addition, key market participants' strategic initiatives will provide structural integrity and future growth opportunities for the market.

Rising cases of cervical cancer

If detected early and managed effectively, cervical cancer is one of the most successfully treatable forms once diagnosed. Late-stage cancers can also be controlled with the correct treatment and palliative care. Cervical cancer can be eliminated within a single generation if enough measures are taken in prevention, screening, and treatment. Several advanced laboratory tests, instruments, and procedures that evaluate abnormal cells and strains of the human papillomavirus (HPV) are used to diagnose cervical cancer. Consequently, the growing incidence of cervical cancer and its treatability following early diagnosis will increase the demand.

Market Restraining Factors

A lack of qualified medical personnel

By 2035, there will likely be a shortage of 12.9 million healthcare workers, an increase from the 7.2 million that exist today. According to recent WHO research, the lack of healthcare workers might have a catastrophic impact on the health of billions of people worldwide if prompt actions are not taken. One reason contributing to this situation is the aging of the workforce, which causes retirements or leaves for higher-paying employment without comparable replacements. Additionally, the sector lacks fresh hires and offers inadequate training. The identification and treatment of illnesses like cervical cancer would be significantly impacted by a global scarcity of healthcare experts, which would impede the market growth.

Type Outlook

Based on type, the market is segmented into pap smear tests, HPV test, biopsy & ECC, colposcopy tests and others. The pap smear tests segment dominated the market with maximum revenue share in 2022. This is because more people are using Pap smear tests to diagnose cervical cancer. The Pap test aids in identifying abnormal cervix cells that may later progress to cancer. Due to this test's great efficiency, it makes up the majority of the shares. Additionally, this segment is growing as early diagnosis is becoming increasingly popular.

Age Group Outlook

On the basis of age group, the market is divided into 20 to 40 years and above 40 years. The above 40 years segment procured a substantial revenue share in the market in 2022. This is owing to the increased government support for cervical cancer diagnosis. Many elderly women are unaware that the risk of developing cervical cancer persists with age, increasing the demand and importance of diagnosis. In addition, approximately one-fifth of cervical cancer cases are diagnosed in women aged 65 and older, propelling the segment's expansion.

Regional Outlook

Region-wise, the market is analyzed across North America, Europe, Asia Pacific, and LAMEA. The North America region witnessed the largest revenue share in the market in 2022. This is due to the increasing number of patients utilizing cervical cancer diagnosis services in hospitals, an increase in the number of market participants, joined with the rising availability of products in the region. In addition, the large market share is attributable to the high level of disease prevention awareness among women in the region, as well as the numerous initiatives introduced to prevent cervical cancer, which has expanded insurance coverage for cervical screening tests, particularly for low-income women, which is aiding the market growth in the region.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Abbott Laboratories, Becton, Dickinson and Company, Carl Zeiss AG, CooperSurgical, Inc. (The Cooper Companies, Inc.), DYSIS Medical, Inc., F. Hoffmann-La Roche Ltd., Hologic, Inc., Qiagen N.V., Siemens Healthineers AG (Siemens AG) and Thermo Fisher Scientific, Inc.

Recent Strategies deployed in Cervical Cancer Diagnostic Market

Acquisition and Mergers:

Jul-2022: Becton, Dickinson, and Company acquired Parata Systems, a pharmacy automation solutions provider. The acquisition aids the company in its growth strategy and allows the company to expand into the high-growth pharmacy automation sector.

Feb-2022: Becton, Dickinson, and Company acquired Cytognos, a flow cytometry solutions provider. The acquisition provides Becton, Dickinson, and Company with Euroflow Consortium which further allows the company to expand their capabilities into Post treatment monitoring.

May-2021: Roche announced the acquisition of GenMark Diagnostics, a molecular diagnostics company. The acquisition expands Roche's molecular diagnostics portfolio and enhances its capabilities in syndromic testing.

Apr-2021: Siemens Healthineers AG acquired Varian Medical Systems, Inc., a radiation oncology treatments provider. This acquisition places Siemens Healthineers AG as a major player in the MedTech sector.

Partnerships, Collaborations, and Agreements:

May-2023: Roche Diagnostics signed an agreement with Cancer Awareness Prevention and Early Detection Trust (CAPED), a non-profit organization aiming at spreading Cancer Awareness. The partnership aims at improving the situation of cervical cancer in India. The partnership is part of Roche's efforts to enhance cancer care around the world.

Aug-2022: Becton, Dickinson, and Company announced a partnership with LabCorp, a life science company. The partnership aims at developing and selling flow cytometry-based companion diagnostics (CDx). The partnership allows BD to serve its customers in a better way by providing solutions for cancer diagnostics.

Jul-2021: QIAGEN partnered with Sysmex Corporation, a healthcare company based in Japan. The partnership aims at developing cancer companion diagnostics by utilizing Qiagen's expertise and Sysmex's Plasma-Safe-SeqS technology. The partnership provides the company with NGS capabilities and would allow the company to serve its partners in a better way.

Feb-2021: Hologic, Inc. partnered with Google Cloud, a range of cloud-based services offered by Google. The partnership aims at enhancing cancer screening and removal of cervical cancer around the world by integrating google cloud's machine learning (MI) technology with Holigic's Genius™ Digital Diagnostics System. The partnership enhances Hologic's position as a premier provider of cancer screening solutions.

Trials and approvals:

Feb-2023: Becton, Dickinson, and Company have received approval from U.S. Food and Drug Administration (FDA) for its BD Onclarity™ HPV Assay. The BD Onclarity™ HPV Assay is used to detect human papillomavirus (HPV).

May-2021: Hologic received premarket approval for its ThinPrep GenesisTM processor. ThinPrep GenesisTM processor is used for specimen transfer and cytology processing applications. The features of the product include barcode scanning, sample aliquoting, slide labelling, and vial uncapping/capping.

Product Launches and Product Expansions:

May-2023: Becton, Dickinson, and Company unveiled BD FACSDiscover S8 Cell Sorter. BD FACSDiscover S8 Cell Sorter is used for detailed profiling of cells. The BD FACSDiscover S8 Cell Sorter features BD CellView Image Technology and BD SpectralFX Technology. The BD CellView Image Technology is used for cell characteristics sorting by providing the researchers with high-quality images of cells. The With BD SpectralFX Technology is used for full range cell sorting using AI-based algorithms and optical architecture.

Apr-2023: QIAGEN unveiled QIAseq Targeted cfDNA Ultra Panels. The QIAseq Targeted cfDNA Ultra Panels were designed for use by researchers for converting cfDNA liquid biopsy samples into libraries for further use in next-generation sequencing (NGS).

Jun-2022: Roche unveiled cobas HPV. The cobas HPV is a human papillomavirus (HPV) self-sampling solution that is designed for use by female patients to collect their samples.

Jul-2021: DYSIS Medical Ltd. announced the launch of DYSIS View. The DYSIS View is used for finding out cervical lesions. The DYSIS view features cervical mapping technology, DYSIS SMARTtrack, and a camera used for high-quality images and exam videos.

Aug-2021: Becton, Dickinson, and Company unveiled BD COR System, a self-controlled diagnostic system used for automating molecular laboratory workflow. The system features scalability, modularity, and onboard capacity for reagents. Furthermore, the system features a PX instrument, used for preparing samples, and GX instrument used for performing analysis.

Apr-2021: Hologic, Inc. unveiled Genius Digital Diagnostics System. Genius Digital Diagnostics System is used for detecting cervical cancer. The Genius Digital Diagnostics System features ThinPrep Pap test image to provide a single view image of relevant cells and GeniusTM Cervical AI that is used in sorting cells to AI-generated gallery.

Geographical Expansions:

Mar-2022: Hologic opened an innovation centre in France. The new centre would serve as a research and development and training hub for the company. The new centre aids the company in providing new technologies to the European market.

Scope of the Study

Market Segments covered in the Report:

By Type

• Pap Smear Tests
• Colposcopy Tests
• HPV Test
• Biopsy & ECC
• Others

By Age Group

• 20 to 40 years
• Above 40 years

By Geography

• North America
  • US
  • Canada
  • Mexico
  • Rest of North America
• Europe
  • Germany
  • UK
  • France
  • Russia
  • Spain
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Singapore
  • Malaysia
  • Rest of Asia Pacific
• LAMEA
  • Brazil
  • Argentina
  • UAE
  • Saudi Arabia
  • South Africa
  • Nigeria
  • Rest of LAMEA

Companies Profiled

• Abbott Laboratories
• Becton, Dickinson and Company
• Carl Zeiss AG
• CooperSurgical, Inc. (The Cooper Companies, Inc.)
• DYSIS Medical, Inc.
• F. Hoffmann-La Roche Ltd.
• Hologic, Inc.
• Qiagen N.V.
• Siemens Healthineers AG (Siemens AG)
• Thermo Fisher Scientific, Inc.

Unique Offerings from KBV Research

• Exhaustive coverage
• Highest number of market tables and figures
• Subscription based model available
• Guaranteed best price
• Assured post sales research support with 10% customization free

Table of Contents

Chapter 1. Market Scope & Methodology

• 1.1 Market Definition
• 1.2 Objectives
• 1.3 Market Scope
• 1.4 Segmentation
  • 1.4.1 Global Cervical Cancer Diagnostic Market, by Type
  • 1.4.2 Global Cervical Cancer Diagnostic Market, by Age Group
  • 1.4.3 Global Cervical Cancer Diagnostic Market, by Geography
• 1.5 Methodology for the research

Chapter 2. Market Overview

• 2.1 Introduction
  • 2.1.1 Overview
    • 2.1.1.1 Market composition & scenario
• 2.2 Key Factors Impacting the Market
  • 2.2.1 Market Drivers
  • 2.2.2 Market Restraints

Chapter 3. Competition Analysis - Global

• 3.1 KBV Cardinal Matrix
  • 3.1.1 Partnerships, Collaborations and Agreements
  • 3.1.2 Product Launches and Product Expansions
  • 3.1.3 Acquisition and Mergers
  • 3.1.4 Approvals and Trials
  • 3.1.5 Geographical and Business Expansions
• 3.2 Top Winning Strategies
  • 3.2.1 Key Leading Strategies: Percentage Distribution (2019-2023)

Chapter 4. Global Cervical Cancer Diagnostic Market by Type

• 4.1 Global Pap Smear Tests Market by Region
• 4.2 Global Colposcopy Tests Market by Region
• 4.3 Global HPV Test Market by Region
• 4.4 Global Biopsy & ECC Market by Region
• 4.5 Global Others Market by Region

Chapter 5. Global Cervical Cancer Diagnostic Market by Age Group

• 5.1 Global 20 to 40 years Market by Region
• 5.2 Global Above 40 years Market by Region

Chapter 6. Global Cervical Cancer Diagnostic Market by Region

• 6.1 North America Cervical Cancer Diagnostic Market
  • 6.1.1 North America Cervical Cancer Diagnostic Market by Type
    • 6.1.1.1 North America Pap Smear Tests Market by Country
    • 6.1.1.2 North America Colposcopy Tests Market by Country
    • 6.1.1.3 North America HPV Test Market by Country
    • 6.1.1.4 North America Biopsy & ECC Market by Country
    • 6.1.1.5 North America Others Market by Country
  • 6.1.2 North America Cervical Cancer Diagnostic Market by Age Group
    • 6.1.2.1 North America 20 to 40 years Market by Country
    • 6.1.2.2 North America Above 40 years Market by Country
  • 6.1.3 North America Cervical Cancer Diagnostic Market by Country
    • 6.1.3.1 US Cervical Cancer Diagnostic Market
      • 6.1.3.1.1 US Cervical Cancer Diagnostic Market by Type
      • 6.1.3.1.2 US Cervical Cancer Diagnostic Market by Age Group
    • 6.1.3.2 Canada Cervical Cancer Diagnostic Market
      • 6.1.3.2.1 Canada Cervical Cancer Diagnostic Market by Type
      • 6.1.3.2.2 Canada Cervical Cancer Diagnostic Market by Age Group
    • 6.1.3.3 Mexico Cervical Cancer Diagnostic Market
      • 6.1.3.3.1 Mexico Cervical Cancer Diagnostic Market by Type
      • 6.1.3.3.2 Mexico Cervical Cancer Diagnostic Market by Age Group
    • 6.1.3.4 Rest of North America Cervical Cancer Diagnostic Market
      • 6.1.3.4.1 Rest of North America Cervical Cancer Diagnostic Market by Type
      • 6.1.3.4.2 Rest of North America Cervical Cancer Diagnostic Market by Age Group
• 6.2 Europe Cervical Cancer Diagnostic Market
  • 6.2.1 Europe Cervical Cancer Diagnostic Market by Type
    • 6.2.1.1 Europe Pap Smear Tests Market by Country
    • 6.2.1.2 Europe Colposcopy Tests Market by Country
    • 6.2.1.3 Europe HPV Test Market by Country
    • 6.2.1.4 Europe Biopsy & ECC Market by Country
    • 6.2.1.5 Europe Others Market by Country
  • 6.2.2 Europe Cervical Cancer Diagnostic Market by Age Group
    • 6.2.2.1 Europe 20 to 40 years Market by Country
    • 6.2.2.2 Europe Above 40 years Market by Country
  • 6.2.3 Europe Cervical Cancer Diagnostic Market by Country
    • 6.2.3.1 Germany Cervical Cancer Diagnostic Market
      • 6.2.3.1.1 Germany Cervical Cancer Diagnostic Market by Type
      • 6.2.3.1.2 Germany Cervical Cancer Diagnostic Market by Age Group
    • 6.2.3.2 UK Cervical Cancer Diagnostic Market
      • 6.2.3.2.1 UK Cervical Cancer Diagnostic Market by Type
      • 6.2.3.2.2 UK Cervical Cancer Diagnostic Market by Age Group
    • 6.2.3.3 France Cervical Cancer Diagnostic Market
      • 6.2.3.3.1 France Cervical Cancer Diagnostic Market by Type
      • 6.2.3.3.2 France Cervical Cancer Diagnostic Market by Age Group
    • 6.2.3.4 Russia Cervical Cancer Diagnostic Market
      • 6.2.3.4.1 Russia Cervical Cancer Diagnostic Market by Type
      • 6.2.3.4.2 Russia Cervical Cancer Diagnostic Market by Age Group
    • 6.2.3.5 Spain Cervical Cancer Diagnostic Market
      • 6.2.3.5.1 Spain Cervical Cancer Diagnostic Market by Type
      • 6.2.3.5.2 Spain Cervical Cancer Diagnostic Market by Age Group
    • 6.2.3.6 Italy Cervical Cancer Diagnostic Market
      • 6.2.3.6.1 Italy Cervical Cancer Diagnostic Market by Type
      • 6.2.3.6.2 Italy Cervical Cancer Diagnostic Market by Age Group
    • 6.2.3.7 Rest of Europe Cervical Cancer Diagnostic Market
      • 6.2.3.7.1 Rest of Europe Cervical Cancer Diagnostic Market by Type
      • 6.2.3.7.2 Rest of Europe Cervical Cancer Diagnostic Market by Age Group
• 6.3 Asia Pacific Cervical Cancer Diagnostic Market
  • 6.3.1 Asia Pacific Cervical Cancer Diagnostic Market by Type
    • 6.3.1.1 Asia Pacific Pap Smear Tests Market by Country
    • 6.3.1.2 Asia Pacific Colposcopy Tests Market by Country
    • 6.3.1.3 Asia Pacific HPV Test Market by Country
    • 6.3.1.4 Asia Pacific Biopsy & ECC Market by Country
    • 6.3.1.5 Asia Pacific Others Market by Country
  • 6.3.2 Asia Pacific Cervical Cancer Diagnostic Market by Age Group
    • 6.3.2.1 Asia Pacific 20 to 40 years Market by Country
    • 6.3.2.2 Asia Pacific Above 40 years Market by Country
  • 6.3.3 Asia Pacific Cervical Cancer Diagnostic Market by Country
    • 6.3.3.1 China Cervical Cancer Diagnostic Market
      • 6.3.3.1.1 China Cervical Cancer Diagnostic Market by Type
      • 6.3.3.1.2 China Cervical Cancer Diagnostic Market by Age Group
    • 6.3.3.2 Japan Cervical Cancer Diagnostic Market
      • 6.3.3.2.1 Japan Cervical Cancer Diagnostic Market by Type
      • 6.3.3.2.2 Japan Cervical Cancer Diagnostic Market by Age Group
    • 6.3.3.3 India Cervical Cancer Diagnostic Market
      • 6.3.3.3.1 India Cervical Cancer Diagnostic Market by Type
      • 6.3.3.3.2 India Cervical Cancer Diagnostic Market by Age Group
    • 6.3.3.4 South Korea Cervical Cancer Diagnostic Market
      • 6.3.3.4.1 South Korea Cervical Cancer Diagnostic Market by Type
      • 6.3.3.4.2 South Korea Cervical Cancer Diagnostic Market by Age Group
    • 6.3.3.5 Singapore Cervical Cancer Diagnostic Market
      • 6.3.3.5.1 Singapore Cervical Cancer Diagnostic Market by Type
      • 6.3.3.5.2 Singapore Cervical Cancer Diagnostic Market by Age Group
    • 6.3.3.6 Malaysia Cervical Cancer Diagnostic Market
      • 6.3.3.6.1 Malaysia Cervical Cancer Diagnostic Market by Type
      • 6.3.3.6.2 Malaysia Cervical Cancer Diagnostic Market by Age Group
    • 6.3.3.7 Rest of Asia Pacific Cervical Cancer Diagnostic Market
      • 6.3.3.7.1 Rest of Asia Pacific Cervical Cancer Diagnostic Market by Type
      • 6.3.3.7.2 Rest of Asia Pacific Cervical Cancer Diagnostic Market by Age Group
• 6.4 LAMEA Cervical Cancer Diagnostic Market
  • 6.4.1 LAMEA Cervical Cancer Diagnostic Market by Type
    • 6.4.1.1 LAMEA Pap Smear Tests Market by Country
    • 6.4.1.2 LAMEA Colposcopy Tests Market by Country
    • 6.4.1.3 LAMEA HPV Test Market by Country
    • 6.4.1.4 LAMEA Biopsy & ECC Market by Country
    • 6.4.1.5 LAMEA Others Market by Country
  • 6.4.2 LAMEA Cervical Cancer Diagnostic Market by Age Group
    • 6.4.2.1 LAMEA 20 to 40 years Market by Country
    • 6.4.2.2 LAMEA Above 40 years Market by Country
  • 6.4.3 LAMEA Cervical Cancer Diagnostic Market by Country
    • 6.4.3.1 Brazil Cervical Cancer Diagnostic Market
      • 6.4.3.1.1 Brazil Cervical Cancer Diagnostic Market by Type
      • 6.4.3.1.2 Brazil Cervical Cancer Diagnostic Market by Age Group
    • 6.4.3.2 Argentina Cervical Cancer Diagnostic Market
      • 6.4.3.2.1 Argentina Cervical Cancer Diagnostic Market by Type
      • 6.4.3.2.2 Argentina Cervical Cancer Diagnostic Market by Age Group
    • 6.4.3.3 UAE Cervical Cancer Diagnostic Market
      • 6.4.3.3.1 UAE Cervical Cancer Diagnostic Market by Type
      • 6.4.3.3.2 UAE Cervical Cancer Diagnostic Market by Age Group
    • 6.4.3.4 Saudi Arabia Cervical Cancer Diagnostic Market
      • 6.4.3.4.1 Saudi Arabia Cervical Cancer Diagnostic Market by Type
      • 6.4.3.4.2 Saudi Arabia Cervical Cancer Diagnostic Market by Age Group
    • 6.4.3.5 South Africa Cervical Cancer Diagnostic Market
      • 6.4.3.5.1 South Africa Cervical Cancer Diagnostic Market by Type
      • 6.4.3.5.2 South Africa Cervical Cancer Diagnostic Market by Age Group
    • 6.4.3.6 Nigeria Cervical Cancer Diagnostic Market
      • 6.4.3.6.1 Nigeria Cervical Cancer Diagnostic Market by Type
      • 6.4.3.6.2 Nigeria Cervical Cancer Diagnostic Market by Age Group
    • 6.4.3.7 Rest of LAMEA Cervical Cancer Diagnostic Market
      • 6.4.3.7.1 Rest of LAMEA Cervical Cancer Diagnostic Market by Type
      • 6.4.3.7.2 Rest of LAMEA Cervical Cancer Diagnostic Market by Age Group

Chapter 7. Company Profiles

• 7.1 Abbott Laboratories
  • 7.1.1 Company Overview
  • 7.1.2 Financial Analysis
  • 7.1.3 Segmental and Regional Analysis
  • 7.1.4 Research & Development Expense
  • 7.1.5 SWOT Analysis
• 7.2 Becton, Dickinson and Company
  • 7.2.1 Company Overview
  • 7.2.2 Financial Analysis
  • 7.2.3 Segmental and Regional Analysis
  • 7.2.4 Research & Development Expense
  • 7.2.5 Recent strategies and developments:
    • 7.2.5.1 Partnerships, Collaborations, and Agreements:
    • 7.2.5.2 Product Launches and Product Expansions:
    • 7.2.5.3 Acquisition and Mergers:
  • 7.2.6 SWOT Analysis
• 7.3 Carl Zeiss AG
  • 7.3.1 Company Overview
  • 7.3.2 Financial Analysis
  • 7.3.3 Segmental and Regional Analysis
  • 7.3.4 Research & Development Expenses
• 7.4 CooperSurgical, Inc. (The Cooper Companies, Inc.)
  • 7.4.1 Company Overview
  • 7.4.2 Financial Analysis
  • 7.4.3 Segmental and Regional Analysis
  • 7.4.4 Research & Development Expense
• 7.5 DYSIS Medical, Inc.
  • 7.5.1 Company Overview
  • 7.5.2 Recent strategies and developments:
    • 7.5.2.1 Product Launches and Product Expansions:
• 7.6 F. Hoffmann-La Roche Ltd.
  • 7.6.1 Company Overview
  • 7.6.2 Financial Analysis
  • 7.6.3 Segmental and Regional Analysis
  • 7.6.4 Research & Development Expense
  • 7.6.5 Recent strategies and developments:
    • 7.6.5.1 Partnerships, Collaborations, and Agreements:
    • 7.6.5.2 Product Launches and Product Expansions:
    • 7.6.5.3 Acquisition and Mergers:
• 7.7 Hologic, Inc.
  • 7.7.1 Company Overview
  • 7.7.2 Financial Analysis
  • 7.7.3 Segmental and Regional Analysis
  • 7.7.4 Research & Development Expenses
  • 7.7.5 Recent strategies and developments:
    • 7.7.5.1 Partnerships, Collaborations, and Agreements:
    • 7.7.5.2 Product Launches and Product Expansions:
    • 7.7.5.3 Geographical Expansions:
• 7.8 Qiagen N.V.
  • 7.8.1 Company Overview
  • 7.8.2 Financial Analysis
  • 7.8.3 Regional Analysis
  • 7.8.4 Research & Development Expense
  • 7.8.5 Recent strategies and developments:
    • 7.8.5.1 Partnerships, Collaborations, and Agreements:
    • 7.8.5.2 Product Launches and Product Expansions:
    • 7.8.5.3 Acquisition and Mergers:
• 7.9 Siemens Healthineers AG (Siemens AG)
  • 7.9.1 Company Overview
  • 7.9.2 Financial Analysis
  • 7.9.3 Segmental and Regional Analysis
  • 7.9.4 Research & Development Expense
  • 7.9.5 SWOT Analysis
• 7.10. Thermo Fisher Scientific, Inc.
  • 7.10.1 Company Overview
  • 7.10.2 Financial Analysis
  • 7.10.3 Segmental and Regional Analysis
  • 7.10.4 Research & Development Expenses
  • 7.10.5 SWOT Analysis